This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Learn which credit cards offer valuable points and cash back benefits. Choose the right card to enhance your financial rewards.
28,655 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Hyped up rare-earth plays attract attention, but many stumble before they mine. This guide breaks down how to assess ...
Pfizer’s stock has faced waves of headwinds, but a patient, long-term view can reveal an opportunity. This guide expl...
Markets rally as AI progress accelerates, steering investment toward compute, energy, and robotics. Analysts warn the...
As Rivian gears up for the upcoming earnings release, two major catalysts could shape the stock's trajectory. This gu...
As Gap readies its (gap) 2025 earnings call, investors want clarity on brand performance, margins, and 2026 guidance....
A focused look at a nuclear energy stock with small modular reactors (SMRs) at the center. Learn the potential upside...
Fresh analyst calls are steering the early-week mood on Wall Street. Dell Technologies, BioMarin, Disney, HubSpot and...
Canopy Growth has seen dramatic swings, trading under $2 after years of highs. This guide breaks down what could push...
A handful of iconic dividend payers have fallen this year, but market watchers see potential upside as earnings stay ...
A fresh cash-raising move and a strategic acquisition shook investors in Intuitive Machines. This article breaks down...
BioNTech’s stock is under pressure as investors react to weak guidance and leadership pivots. This deep dive breaks d...